OBJECTIVES: Positron emission tomography with CT (PET/CT) scanning is increasingly being used in head and neck cancer to assess response after radical concomitant chemoradiotherapy. The purpose of this study was to assess the use of PET/CT following chemoradiotherapy at our institution. METHODS: All patients receiving radical chemoradiotherapy for head and neck cancer over a 9-year period were retrospectively identified. Outcome data including local control and overall survival were collected for all patients. The negative predictive value of PET/CT for local recurrence was calculated. Of those with a reported positive PET/CT scan the maximum standardised uptake values were compared with the incidence of local recurrence. RESULTS: 92 patients were identified having a post-treatment PET/CT from a total of 301 patients receiving radical concomitant chemoradiotherapy. Median time from completion of chemoradiotherapy to PET/CT scan was 3 (range 2-8) months. Median follow-up in surviving patients was 19 and 25 months in the PET/CT and non-PET/CT groups, respectively. The negative predictive value for local recurrence was 91.8%. The median maximum standardised uptake values were 10.2 (range 3.1-33) and 6.89 (range 3.1-30) in those with local recurrence and with no local recurrence, respectively. CONCLUSIONS: Post-chemoradiotherapy PET/CT may aid subsequent management decisions. Patients with a negative PET/CT scan after radical chemoradiotherapy have a 91.8% chance of remaining free of local recurrence 19 months post-treatment. A higher maximum standardised uptake value on the post-chemoradiotherapy PET/CT may predict subsequent local recurrence and warrants further investigation. Advances in knowledge Post-chemoradiotherapy PET/CT imaging aids subsequent management decisions.
OBJECTIVES: Positron emission tomography with CT (PET/CT) scanning is increasingly being used in head and neck cancer to assess response after radical concomitant chemoradiotherapy. The purpose of this study was to assess the use of PET/CT following chemoradiotherapy at our institution. METHODS: All patients receiving radical chemoradiotherapy for head and neck cancer over a 9-year period were retrospectively identified. Outcome data including local control and overall survival were collected for all patients. The negative predictive value of PET/CT for local recurrence was calculated. Of those with a reported positive PET/CT scan the maximum standardised uptake values were compared with the incidence of local recurrence. RESULTS: 92 patients were identified having a post-treatment PET/CT from a total of 301 patients receiving radical concomitant chemoradiotherapy. Median time from completion of chemoradiotherapy to PET/CT scan was 3 (range 2-8) months. Median follow-up in surviving patients was 19 and 25 months in the PET/CT and non-PET/CT groups, respectively. The negative predictive value for local recurrence was 91.8%. The median maximum standardised uptake values were 10.2 (range 3.1-33) and 6.89 (range 3.1-30) in those with local recurrence and with no local recurrence, respectively. CONCLUSIONS: Post-chemoradiotherapy PET/CT may aid subsequent management decisions. Patients with a negative PET/CT scan after radical chemoradiotherapy have a 91.8% chance of remaining free of local recurrence 19 months post-treatment. A higher maximum standardised uptake value on the post-chemoradiotherapy PET/CT may predict subsequent local recurrence and warrants further investigation. Advances in knowledge Post-chemoradiotherapy PET/CT imaging aids subsequent management decisions.
Authors: T S Boyd; P M Harari; S P Tannehill; M C Voytovich; G K Hartig; C N Ford; R L Foote; B H Campbell; C J Schultz Journal: Head Neck Date: 1998-03 Impact factor: 3.147
Authors: Sravana K Chennupati; Andrew Quon; Aya Kamaya; Reetesh K Pai; Trang La; Trevor E Krakow; Edward Graves; Albert C Koong; Daniel T Chang Journal: Am J Clin Oncol Date: 2012-08 Impact factor: 2.339
Authors: Seng Chuan Ong; Heiko Schöder; Nancy Y Lee; Snehal G Patel; Diane Carlson; Matthew Fury; David G Pfister; Jatin P Shah; Steven M Larson; Dennis H Kraus Journal: J Nucl Med Date: 2008-03-14 Impact factor: 10.057
Authors: Jayakar V Nayak; Rohan R Walvekar; Regiane S Andrade; Nicole Daamen; Stephen Y Lai; Athanassios Argiris; Ryan P Smith; Dwight E Heron; Robert L Ferris; Jonas T Johnson; Barton F Branstetter Journal: Laryngoscope Date: 2007-12 Impact factor: 3.325
Authors: Min Yao; Russell B Smith; Henry T Hoffman; Gerry F Funk; Minggen Lu; Yusuf Menda; Michael M Graham; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2008-10-17 Impact factor: 7.038
Authors: Alexander Langerman; Colleen Plein; Everett E Vokes; Joseph K Salama; Daniel J Haraf; Elizabeth A Blair; Kerstin M Stenson Journal: Arch Otolaryngol Head Neck Surg Date: 2009-11
Authors: Sweet Ping Ng; Courtney Pollard; Joel Berends; Zeina Ayoub; Mona Kamal; Adam S Garden; Houda Bahig; Scott B Cantor; Andrew J Schaefer; Temitayo Ajayi; G Brandon Gunn; Steven J Frank; Heath Skinner; Jack Phan; William H Morrison; Renata Ferrarotto; Jason M Johnson; Abdallah S R Mohamed; Stephen Y Lai; Amy C Hessel; Erich M Sturgis; Randal S Weber; Clifton D Fuller; David I Rosenthal Journal: Cancer Date: 2019-02-12 Impact factor: 6.860
Authors: Ayse Tuba Kendi; David Brandon; Jeffrey Switchenko; Jeffery Trad Wadsworth; Mark W El-Deiry; Nabil F Saba; David M Schuster; Rathan M Subramaniam Journal: Am J Nucl Med Mol Imaging Date: 2017-09-01
Authors: Vasavi Paidpally; Alin Chirindel; Christine H Chung; Jeremy Richmon; Wayne Koch; Harry Quon; Rathan M Subramaniam Journal: AJR Am J Roentgenol Date: 2014-08 Impact factor: 3.959
Authors: Charles Marcus; Anthony Ciarallo; Abdel K Tahari; Esther Mena; Wayne Koch; Richard L Wahl; Ana P Kiess; Hyunseok Kang; Rathan M Subramaniam Journal: J Nucl Med Date: 2014-06-19 Impact factor: 10.057
Authors: S Connor; C Sit; M Anjari; M Lei; T Guerrero-Urbano; T Szyszko; G Cook; P Bassett; V Goh Journal: J Cancer Res Clin Oncol Date: 2021-06-22 Impact factor: 4.553